Emcure Pharmaceuticals

Emcure Pharmaceuticals, headquartered at Pune in West India, is an Indian pharmaceutical company. The company's products include tablets, capsules (both softgel capsules and hard-gel capsules), and injectables.

Emcure Pharmaceuticals Limited
MNC (JVs and subsidiaries)
IndustryPharmaceutical
Founded1983
HeadquartersHinjwadi, Pune, India
Key people
Satish Mehta[1] CEO,

Namita Thapar[2] Executive Director,

Vik Thapar[3] President - Corporate Dev & Strategy,

Samit Mehta[4] President - R&D
Productstablets, capsules, softgels, injectables, Lyophilized sterile parenterals, Onco products
US$220 million
Number of employees
11000+
Websitewww.emcure.com

Indian plants
  • Solid Dosage facility at Hinjawadi - In 2006, Emcure received US FDA approval for its solid dosages facility at Hinjwadi, Pune. The plant manufactures solid oral formulations for the international regulated markets.
  • Small volume parenteral facility at Hinjawadi - US FDA, UK MHRA approved. Has lyophilization and pfs capability
  • Oncology injectable facility at Hinjawadi
  • Solid Orals facilities at Jammu and Bhosari
  • API facility at Kurkumbh- USFDA approved
  • Biotech facility at Hinjawadi
  • R&D center at gandhinagar and plant at sanand Ahmedabad.- Sanand facility is US FDA approved

US plant

USA - The company has a manufacturing facility and R&D center at East Brunswick, New Jersey, USA.

Capital markets

Emcure is planning to raise money through an initial public offering for some time now [5] In 2014, Blackstone sold its stake in Emcure to Bain Capital [6]

Recalls

In 2010, Pfizer had to recall three batches of an anti-bacterial product from the US market due to presence of Bacillus anthracis, Penicillium chrysogenum & E. coli in some samples.[7] Teva recalled several batches of two products due to white tablets showing presence of Yersinia pestis in 2011.[8]


AIDS Initiative

Emcure voices its concerns on HIV/AIDS through its "Let's fight AIDS together" initiative and supplies Antiretroviral drugs to Africa, Asia Pacific and CIS. As a part of its corporate social responsibility it supports 'Taal', a pharmacy for HIV/AIDS patients run by HIV/AIDS patients.

Emcure has license agreements with Bristol-Myers Squibb for Atazanavir [9] and Gilead Sciences for Tenofovir [10] as part of their Global Access Programs.

Anticancer portfolio

Roche has signed a deal with Emcure for manufacturing its blockbuster anticancer drugs Herceptin and Mabthera in India.[11] Under this programme the cancer drugs shall be made available to the developing world at an affordable 'cut-price' version.[12]

Price fixing

Heritage Pharmaceuticals, a division of Emcure has entered into a deferred prosecution agreement [13] with the United States Department of Justice, Antitrust Division ("DOJ") relating to a one-count Information for a conspiracy involving glyburide. In conjunction with the DPA, Heritage will pay a $225,000 fine.

In addition, the Company separately agreed to a settlement with the United States Department of Justice, Civil Division to resolve potential civil liability under the False Claims Act in connection with the antitrust conduct. Under the terms of the settlement, the Company has agreed to pay $7.1 million. Heritage has agreed to pay $7.1 million as part of a settlement with DOJ's Civil Division to resolve allegations of selling drugs at the artificially inflated prices, which resulted in claims submitted to or purchases by federal healthcare programs

gollark: MultiMC is from the AUR, and recompiling it didn't fix it.
gollark: I tried downgrading Qt but it turns out downgrading is hard and I can't make it work right.
gollark: Lemmmy, you can Linux, right? Do you have any idea why the Qt-using applications (MultiMC, Calibre) I have appear to be segfaulting and/or what I can do about it?
gollark: KDE is resource-intensive, apparently, and LXDE is good enough.
gollark: Hmm. This is very annoying. 5.14.0 doesn't work and 5.13.whatever causes problems because it's a different version to what the applications want.

References
  1. http://investing.businessweek.com/businessweek/research/stocks/private/person.asp?personId=23350262&privcapId=21771338&previousCapId=671980&previousTitle=BLACKSTONE%20GROUP%20LP/THE
  2. https://www.emcure.com/leadership
  3. https://www.emcure.com/leadership
  4. https://www.emcure.com/leadership
  5. http://www.moneycontrol.com/news/ipo-upcoming-issues/emcure-pharma-plans-rs-700-crore-ipo_534950.html
  6. http://archive.indianexpress.com/news/blackstone-to-sell-emcure-pharmaceuticals-stake-to-bain-capital/1209682/
  7. http://articles.economictimes.indiatimes.com/2010-11-11/news/27610085_1_pfizer-american-drug-regulator-manufacturing-norms
  8. "Archived copy". Archived from the original on 2011-05-20. Retrieved 2012-04-25.CS1 maint: archived copy as title (link)
  9. http://www.business-standard.com/india/news/bristol-myers-outsources-aids-drug-to-emcure/233222/
  10. http://findarticles.com/p/news-articles/times-of-india-the/mi_8012/is_20060818/gilead-inks-offer-tenofovir/ai_n39427224/
  11. http://articles.economictimes.indiatimes.com/2012-03-02/news/31117087_1_emcure-pharmaceuticals-anti-hiv-drugs-emcure-signs-deal
  12. "Archived copy". Archived from the original on 2012-08-01. Retrieved 2012-04-12.CS1 maint: archived copy as title (link)
  13. https://www.justice.gov/opa/pr/pharmaceutical-company-admits-price-fixing-violation-antitrust-law-resolves-related-false
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.